Germany's Merck KGaA said it acquired Wilbraham, Mass.-based FloDesign Sonics Inc.
FloDesign Sonics is a private biotechnology company which offers an acoustic cell processing platform for the industrialization of cell and gene therapy manufacturing.
Financial terms were not disclosed.
The acquisition of FloDesign Sonics will industrialize the manufacturing of autologous cell therapy, allowing treatments such as CAR-T cell therapies to reach patients faster, said Udit Batra, a member of Merck's executive board and CEO of its life science division.
Merck said it is the first company to make acoustic technology available for cell therapy manufacturing.
Merck recently closed its €5.8 billion acquisition of Versum Materials Inc.
